Introduction
============

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent disease that results from excessive fat accumulation in the liver. NAFLD not only affects the adult population (about 20--40% of adults in Western countries have fatty liver) \[[@b1]\], but is also the most common cause of paediatric liver disease \[[@b2]\].

NAFLD is now recognized as the hepatic manifestation of the metabolic syndrome (MS). In fact, there is a nearly universal association between MS comorbidities and NAFLD, because obesity, type 2 diabetes and hyperlipidaemia are known to co-exist in patients with fatty liver. NAFLD is also related to increased risk of cardiovascular diseases, such as carotid atherosclerosis \[[@b3]\]. Although many risk factors of NAFLD are well defined, its pathogenesis remains poorly understood. Recent evidence has implicated insulin resistance as a major contributor to the pathogenesis and disease progression of NAFLD \[[@b4]\]. In addition, NAFLD is associated with increased fatty acid β-oxidation, hepatic oxidative stress and mitochondrial structural defects \[[@b5]\]. For instance, crystalline inclusions are observed in hepatic mitochondria in non-alcoholic steatohepatitis (NASH), and their presence has been correlated either with an adaptive process or mitochondrial injury \[[@b6]\].

Mitochondrial function is critical in the physiopathology of NAFLD because liver mitochondria is a primary site for the oxidation of fatty acids and oxidative phosphorylation -- a process that requires multiple enzymes that are encoded by both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA).

Previous studies have revealed that qualitative and quantitative changes in skeletal muscle mtDNA are involved in the pathogenesis of type 2 diabetes \[[@b7]\]. Moreover, mtDNA content in peripheral blood leucocytes has been associated with insulin resistance in children and adult \[[@b8], [@b9]\]. These findings suggest that mitochondrial density and mtDNA copy number play a role in the mitochondrial dysfunction associated with MS-related phenotypes. However, its role in NAFLD is not well understood.

An interesting mechanism recently related to the pathogenesis of NAFLD is the association between mitochondrial dysfunction and hepatocyte sensitivity to hypoxic stress \[[@b10]\]. Although imbalance in oxygen homeostasis is a well-known mechanism in many pathophysiological processes, including cardiovascular and cerebrovascular disease, cancer, etc., its role in NAFLD is scarcely explored.

Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor involved in cellular and systemic homeostatic response to hypoxia; HIF-1 is a heterodimeric protein complex comprising two subunits, among which, the redox-sensitive HIF-1α is considered to be the major regulator of O~2~-tension-sensitive genes in cells \[[@b11]\]. Interestingly, HIF-1α has been described as an important regulator of mitochondrial biogenesis in muscle \[[@b12]\], whereas sustained hypoxia in brain has been associated with an increase in neuronal mtDNA content \[[@b13]\].

In view of the evidence described earlier, we evaluated the molecular mechanisms that may be involved in the regulation of liver mtDNA content in a high-fat-induced rat model of NAFLD. In particular, we tested the hypothesis that liver mtDNA copy number is associated with liver expression of *HIF-1α*. We also examined liver mRNA abundance of master nuclear genes involved in the regulation of mitochondrial biogenesis and mtDNA transcription and replication. Furthermore, the occurrence of oxidative stress in the liver of high-fat solid diet (HFD)-induced NAFLD was also assessed. Finally, the effect of pharmacological reversion of hepatic steatosis on liver mtDNA content was evaluated. For the intervention experiment we chose telmisartan, an angiotensin II receptor blocker considered also to act as a partial agonist of PPARγ, as we and others previously demonstrated its efficacy in reducing hepatic lipid accumulation and reverting liver steatosis in a rat model of NAFLD \[[@b14], [@b15]\].

Materials and methods
=====================

Animals
-------

Twelve-week-old male Sprague-Dawley rats weighing 280 ± 20 g were purchased from the Research Animal Facility of School of Veterinary Medicine, University of Buenos Aires. All the animals were housed individually with food and water freely available and were maintained at room temperature (23 + 1°C) under a 12 hr light/dark cycle.

All the animals received humane care, and the studies were conducted according to the regulations for the use and care of experimental animals.

After acclimatization for 1 week, the rats were randomly divided into two experimental groups. One group included 10 rats that received standard chow diet (SCD) for 20 weeks, and the quantity of the diet was restricted to that spontaneously consumed at the beginning of the experiment (control group, SCD). The other group, including 15 animals, was allowed *ad libitum* access to HFD (40% (w/w) bovine and porcine fat added to the standard chow, as previously described \[[@b16]\] for the same period of time. In all the animals, food intake and body weight were monitored weekly for the 20 week period.

At the completion of the study, the animals were anesthetized with pentobarbital and killed. Blood from individual rats was collected by cardiac puncture to determine the plasma and serum levels of different biochemical parameters. Food was withdrawn from 8:00 a.m. to 4:00 p.m., before the rats were killed, and the intraperitoneal and retroperitoneal fats were measured by weighting them directly.

Liver was quickly snap-frozen and stored at −76°C until gene expression analysis. A portion of each liver was fixed in 10% formalin for histological analysis. Two additional samples of liver tissue (150 mg) were stored at −80°C for quantifying liver lipids.

Biochemical measurements
------------------------

Serum and sodium ethylenediaminetetraacetic acid plasma were obtained by centrifugation and stored at −80°C until needed. Fasting glucose and serum alanine aminotransferase (ALT) were measured by an automatic biochemical analytical system (Architect, Abbott, Buenos Aires, Argentina). The plasma insulin levels were determined using a commercial quantitative ultrasensitive ELISA rat kit according to the manufacturer's instructions (CRYSTAL CHEM, INC., Downers Grove, IL, USA). Insulin resistance was calculated using the homeostasis model of assessment (HOMA) index (fasting plasma insulin \[μU/ml\]× fasting plasma glucose \[mmol/l\]/22.5).

Histological analysis of liver tissue
-------------------------------------

Formalin-fixed liver tissue was processed, and 5-μm-thick paraffin sections were stained with haematoxylin and eosin and Masson's trichrome (for selective demonstration of collagen fibres and fibrin) and Gomori's reticulin silver impregnation (for the evaluation of reticular fibres and collagen type III/IV) for histological analysis. In both experimental groups, osmium tetroxide staining was also carried out to estimate the degree of hepatic steatosis. The degree of steatosis was assessed irrespective of the experimental groups as previously described \[[@b17]\], based on the percentage of hepatocytes containing macrovesicular fat droplets: grade 0, no steatosis or steatosis \<5%; grade 1, \>5% to \<33% of hepatocytes-containing macrovesicular fat droplets; grade 2, \>33--66% of hepatocytes-containing macrovesicular fat droplets and grade 3, \>66% of hepatocytes containing macrovesicular fat droplets.

Electron microscopy
-------------------

Electron microscopy studies were performed on liver specimens by immersion in 3% glutaraldehyde buffered by cacodile buffer of pH 7.4, and then post-fixed in 1% osmium tetroxide and embedded in epoxy resin (Polibed®, Poly-Sciences, Warrington, PA, USA).

The samples were examined and photographed in an electron microscope (Zeiss EM 109, Zeiss, Oberkochen, Germany), and the sections were evaluated by an electron microscopist (NL).

Measurement of liver triglyceride content
-----------------------------------------

The liver triglyceride content was determined using an automatic biochemical analytical system (Architect, Abbott), and the results were expressed as micrograms of triglyceride per milligram of liver tissue (μg/mg liver).

RNA preparation and Real-Time RT-PCR for quantitative assessment of mRNA expression
-----------------------------------------------------------------------------------

Total RNA was prepared from rat livers using phenol extraction step method, with an additional DNAse digestion. For RT-PCR, 3 μg of total RNA was reverse-transcribed using random hexamers and Moloney murine leukaemia virus (MMLV) reverse transcriptase (Promega, Madison, WI, USA). Real-time PCR was performed for quantitative assessment of mRNA expression in an iCycler thermocycler (BioRad, Hercules, CA, USA) using the fluorescent dye, SYBR-Green (Invitrogen, Buenos Aires, Argentina). All the real-time PCR reactions were run in triplicate and all the samples of the experimental groups were tested. The relative expression of target genes' mRNA was normalized to the amount of a housekeeping gene (peptidylprolyl isomerase A, PPIA, also termed as cyclophilin A) to carry out comparisons between the groups. Cyclophilin was found to be the most stable reference gene for testing liver mRNA expression among other housekeeping genes tested before starting the experiment \[β-actin, TATA box binding protein, and glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*)\]. The levels of mRNA were expressed as the ratio of the estimated amount of the target gene relative to the *PPIA* mRNA levels using fluorescence threshold cycle values (Ct) calculated for each sample, and the estimated efficiency of the PCR for each product was expressed as the average of each sample efficiency value obtained \[[@b18]\].

The specificity of amplification and absence of primer dimers were confirmed using melting curve analysis at the end of each run. The primer sequences and the resulting PCR product lengths are shown [Table 1](#tbl1){ref-type="table"}.

###### 

Primers Used for the mRNA gene expression--PCR reaction and quantification of mtDNA

  **Gene name**                                           **Primer sequence**                                                                       **Amplicon size (bp)**
  ------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------
  HIF1-α                                                  Forward 5′-TGT GTG TGT GAA TTA TGT TG-3′ Reverse 5′-GTC CTC AGA TTC CAC TTT AG-3′         142
  PGC1α                                                   Forward 5′-AAA AGC TTG ACT GGC GTC AT-3′ Reverse 5′-TCA GGA AGA TCT GGG CAA AG-3′         129
  Tfam                                                    Forward 5′-GGC AGA AAC GCC TAA AGA AG-3′ Reverse 5′-TCA TCC TTA GCC TCC TGG AA-3′         127
  *NRF-1*                                                 Forward 5′-CGC AGT GAC GTC CGC ACA GA-3′ Reverse 5′-AAG GTC CTC CCG CCC ATG CT-3′         
  *PPARδ*                                                 Forward 5′-AGG CCT CAG GCT TCC ACT AC-3′ Reverse 5′-TTG CGG TTC TTC TTC TGG AT-3′         130
  COX4I1                                                  Forward 5′-CTT GTC CTG ATC TGG GAG AA-3′ Reverse 5′-GAC CTT CAT GTC CAG CAT CC-3′         105
  PGC1*b*                                                 Forward 5′-TTG ACA GTG GAG CTT TGT GG-3′ Reverse 5′-CTG TGC TTG GTG TCC TGC T-3′          101
  Bax                                                     Forward 5′-CTG CAG AGG ATG ATT GCT GA-3′ Reverse 5′-GGG CAC TTT AGT GCA CAG G-3′          165
  Bcl2                                                    Forward 5′-GAT AAC GGA GGC TGG GAT G-3′ Reverse 5′-CTC ACT TGT GGC CCA GGT AT-3′          151
  Casp3                                                   Forward 5′-GGA CCT GTG GAC CTG AAA AA-3′ Reverse 5′-ATA CCG CAG TCC AGC TCT GT-3′         122
  Col1a1                                                  Forward 5′-GCG TGC TAT GCA AAG AAG ACT-3′ Reverse 5′-TGA CTT CTG CGT CTG GTG AT-3′        105
  Acta2                                                   Forward 5′-TCG GGA CCT CAC TGA CTA CC-3′ Reverse 5′-AAT CCA GGG CGA CAT AAC AC-3′         122
  PPIA                                                    Forward 5′-AGC ACT GGG GAG AAA GGA TT-3′ Reverse 5′-CTT GCC ACC AGT GCC ATT AT-3′         111
  β-actin                                                 Forward 5′-TTC CTG GGT ATG GAA TCC TG-3′ Reverse 5′-CAG CAA TGC CTG GGT ACA T-3′          136
  GAPDH                                                   Forward 5′-CTG ACA TGC CGC CTG GAG AAA C-3′ Reverse 5′-CCA GCA TCA AAG GTG GAA GAA T-3′   161
  TBP                                                     Forward 5′-TGG GAT TGT ACC ACA GCT CCA-3′ Reverse 5′-CTC ATG ATG ACT GCA GCA AAC C-3′     132
  The primer sequences for mtDNA and nDNA amplification                                                                                             
  Rnr2                                                    Forward 5′-AGC TAT TAA TGG TTC GTT TGT-3′ Reverse 5-AGG AGG CTC CAT TTC TCT TGT-3′        132 bp
  GAPDH                                                   Forward 5′-GGA AAG ACA GGT GTT TTG CA-3′ Reverse 5-AGG TCA GAG TGA GCA GGA CA-3′          129 bp

HIF-1α: hypoxia-inducible factor 1, α subunit (basic helix-loop-helix transcription factor); PGC1α: peroxisome proliferator-activated receptor gamma, coactivator 1α; T*fam*: mitochondrial transcription factor A; COX4I1: cytochrome c oxidase subunit IV isoform 1; NRF-1: Nuclear respiratory factor 1; PPARδ: Peroxisome proliferator-activated receptor γ; PGC1β: peroxisome proliferator-activated receptor gamma, coactivator 1β; *Col1a1*: collagen, type I, α~1~; *Acta2*: smooth muscle α-actin; *Bax*: Bcl2-associated X protein; *Bcl2: B-cell*CLL/lymphoma 2; *Casp3*: caspase 3; PPIA: peptidylprolyl isomerase A (cyclophilin A) (relative quantification of gene expression); GAPDH: glyceraldehyde 3-phosphate dehydrogenase; TBP: TATA box binding protein; Rnr2: mitochondrially encoded 16S RNA.

Quantification of mtDNA
-----------------------

An assay based on real-time quantitative PCR was used for both nDNA and mtDNA quantification using SYBR-Green as the fluorescent dye (Invitrogen). For the detection of liver nDNA, we selected *GAPDH* between the nucleotides 1443 and 1571, and for the detection of mtDNA, we selected mitochondrially encoded 16S RNA (*Rnr2*) between the nucleotides 2451 and 2583 \[[@b19]\]. The results were presented as the mtDNA/nDNA ratio. The primer sequences for both mtDNA and nDNA for loading normalization are given in [Table 1](#tbl1){ref-type="table"}.

Triplicate amplifications of mitochondrial and nuclear products were performed separately.

Real-time quantitative PCR was carried out in a BioRad iCycler (Bio-Rad Laboratories, Hercules, CA, USA). The calculation of DNA copy number involved extrapolation from the fluorescence readings in the mode of background subtracted from the readings of BioRad iCycler according to the above-described procedure for gene expression. The specificity of amplification and absence of primer dimers were confirmed using the melting curve analysis at the end of each run.

The two target amplicon sequences (mtDNA and nDNA) were visualized in 2% agarose and purified using Qiagen Qiaex II, Gel extraction Kit (Tecnolab, Buenos Aires, Argentina). The dilutions of the purified amplicons were used as the standard curve to verify the PCR-efficiency values estimated by using the procedure described earlier.

Western blot analysis of liver HIF-1α protein
---------------------------------------------

Nuclear proteins from liver tissue were denatured in SDS sample buffer, separated with 8% SDS-acrylamide gel and electrotransferred to Hybond-hydrophobic polyvinylidene difluoride (PVDF) membranes (GE Healthcare UK Limited, Buckinghamshire, UK). After blocking with 5% non-fat dry milk in tris-buffered saline tween (TBST) buffer (20 mmol/l of Tris-HCl \[pH 7.6\], 137 mmol/l of NaCl, 0.25% of Tween-20), the membranes were probed with rabbit polyclonal anti-HIF-1a (1:1.000) (GeneTex, Inc., GTX30603, Irvine, CA, USA), followed by incubation with horseradish peroxidase (HRP)-conjugated anti-rabbit polyclonal immunoglobulin G secondary antibody (1:15.000) (GeneTex, Inc., GTX26795). Equal protein loading was confirmed by reblotting of the membranes with a goat polyclonal antibody against rabbit polyclonal anti-β-actin (1:500) (GeneTex, Inc., GTX16039). Binding of the antibody was subsequently visualized with enhanced chemiluminescence reagent (GE Healthcare UK Limited), and the band images were detected and analysed using the Lab Works Analysis Software (Ultra-Violet Products Ltd., Cambridge, UK).

Measurement of liver 8-isoprostane
----------------------------------

Measurement of 8-isoprostane (also known as 15-isoprostane F2t, 8-epi-PGF2α, or 8-iso-PGF2α) in liver tissue was carried out using ELISA by employing ethyl acetate extraction method, according to the manufacturer's instruction (Detroit R&D, Inc., Detroit, MI, USA).

Statistical analysis
--------------------

Quantitative data were expressed as mean ± S.E. Pairwise mean differences were evaluated using nonparametric Mann-Whitney test, as most of the variables were ratios and not normally distributed, and non-homogeneous variances between the groups were evident. For the comparison of more than two groups, we used the Kruskal--Wallis test. For testing the differences in steatosis gradation (as a categorical response variable), we used a model with ordinal multinomial distribution and probit as a link function, with animal length and adipose tissue as continuous predictor variables.

The correlation between two variables was determined using Spearman rank correlation test. Logistic and multiple regressions were used on log-transformed variables for testing multivariate association between variables or for adjusting the cofactors.

The data were also adjusted for body weight whenever applicable. A value of *P* \< 0.05 was considered to be statistically significant. We used the Statistica program package, StatSoft (Tulsa, OK, USA), to perform all the analyses.

Experimental results
====================

Effect of HFD on liver histology and organ fat accumulation
-----------------------------------------------------------

HFD-fed rats developed severe hepatic microvesicular and macrovesicular steatosis ([Fig. 1](#fig01){ref-type="fig"}). As shown in [Figure 1G](#fig01){ref-type="fig"}, quantitative evaluation of steatosis score from haematoxylin and eosin and osmium tetroxide staining of liver sections at the end of the experiment demonstrated significant differences between the groups ([ancova]{.smallcaps} with steatosis gradation as a categorical response variable with ordinal multinomial distribution and probit as a link function, with animal length and adipose tissue as continuous predictor variables). This finding was confirmed by biochemical analysis of hepatic triglyceride content ([Fig. 1H](#fig01){ref-type="fig"}).

![Left panel: Liver histology of a representative animal from each experimental group. Haematoxylin and eosin (A and B), Masson's trichrome (C and D), and osmium tetroxide (E and F) staining of liver sections at the end of the experiment. The livers of rats fed with SCD show normal histology and absence of fat accumulation. The livers of rats fed with HFD show severe panlobular micro and macrovesicular steatosis. Arrows indicate large or small droplet steatosis, and lipid globules appear black after osmium tetroxide staining (F). Original magnification: 400×. (G) Quantitative evaluation of steatosis score. Steatosis was given a score from 0 to 3 as described in the 'Materials and methods' section. The data are presented as mean ± S.E. (H) Biochemical analysis of hepatic triglyceride content. The results (μg/mg liver) are expressed as mean ± S.E.](jcmm0015-1329-f1){#fig01}

Furthermore, plasma glucose in the HFD group was not significantly different from that in the SCD group (199 ± 6 mg/dl and 186 ± 7 mg/dl, respectively). Similarly, the plasma insulin levels and HOMA index, despite being lower in the SCD group (96 ± 35 and 45 ± 19 μU/l, respectively), were not statistically different when compared with those observed in the HFD group (187 ± 30 and 96 ± 16 μU/l, respectively). Furthermore, ALT levels (UI/l) were similar in both groups (33 ± 3.2 in SCD rats and 39 ± 2.8 in HFD rats), and HFD rats showed higher visceral fat content at the end of the experiment (26.9 ± 4.5 g) when compared with that in the controls (12.5±5.2 g), *P* \< 0.05.

Effect of HFD on liver mtDNA content and liver mitochondrial density
--------------------------------------------------------------------

As shown in [Figure 2A](#fig02){ref-type="fig"}, we observed that HFD induced a significant increase in liver mtDNA content when compared with that in the SCD rats. In addition, the liver mtDNA/nDNA ratio was significantly correlated with the liver triglyceride content (*R*: 0.29, *P* \< 0.05).

![(A) Liver mtDNA/nDNA ratio assessed by quantitative real-time PCR in each experimental group. Each bar represents the mean ± S.E. values of 10 and 15 animals in SCD and HFD, respectively. mtDNA copy number was calculated as the ratio of *GAPDH* to 16S RNA gene. The results are shown as mtDNA/nDNA ratio. (B) Electron microscopic images depicting the difference in the abundance of the liver mitochondrial density with respect to the mtDNA content. The left-hand picture shows an exemplar of low mtDNA/nDNA ratio, and the right-hand picture shows an exemplar of high mtDNA/nDNA ratio. Original magnification: 12,000×.](jcmm0015-1329-f2){#fig02}

Furthermore, electron microscopic evaluation of liver tissue showed that the observed increase in liver mtDNA copy number was accompanied by higher mitochondrial density ([Fig. 2B](#fig02){ref-type="fig"}).

Liver expression of *HIF-1α* mRNA was significantly associated with liver mtDNA content
---------------------------------------------------------------------------------------

To address the question of whether the increase in liver mtDNA copy number is associated with *HIF-1α*, we examined the liver expression of *HIF-1α* mRNA, and observed a significant positive correlation between liver mtDNA/nDNA ratio and hepatic levels of *HIF-1α* mRNA (*R*: 0.37, *P* \< 0.001). We found that the level of *HIF-1α* mRNA was significantly higher in the HFD group ([Fig. 3A](#fig03){ref-type="fig"}). Western blot analysis showed that the level of protein, in parallel with the liver mRNA *HIF-1α* expression, was also significantly higher in the livers with increased mtDNA/nDNA ratio ([Fig. 3B](#fig03){ref-type="fig"}).

![(A) Liver expression analysis of *HIF-1α* mRNA by quantitative real-time PCR in each experimental group. Each bar represents the mean ± S.E. values of 10 and 15 animals in SCD and HFD, respectively. In each sample, the gene expression was normalized to the expression of cyclophilin A and multiplied by 100. (B) Representative Western blot analysis of liver *HIF-1α* protein expression in each experimental group. Hypoxia-positive control (H) obtained from a rat ischemic skeletal muscle. β-actin was used as loading control.](jcmm0015-1329-f3){#fig03}

Liver expression of cytochrome c oxidase subunit IV isoform 1 (*COX4I1*) mRNA was significantly associated with liver mtDNA content
-----------------------------------------------------------------------------------------------------------------------------------

Cytochrome c oxidase (COX), located in the inner mitochondrial membrane, is a dimer in which each monomer consists of 13 subunits; subunit IV (COX4) is regulated in an O~2~-dependent manner and is also a terminal enzyme in the mitochondrial respiratory chain, which catalyses the electron transfer from reduced cytochrome c to molecular oxygen. COX4 subunit determines the efficiency of mitochondrial respiration in response to different oxygen tensions. In addition, *COX4I1* is a marker of mitochondrial mass. Thus, we evaluated liver *COX4I1* mRNA expression and provided further evidence for an increase in liver mtDNA content, probably mediated by the effect of oxygen concentration in the liver, as the mtDNA/nDNA ratio was positively correlated with *COX4I1* expression (*R*: 0.30, *P* \< 0.02).

Multiple regression analysis showed that liver mtDNA/nDNA ratio was strongly correlated with the expression of *HIF-1α* (β: 0.32, S.E.: ±0.12, *P* \< 0.009) and *COX4I1* (β 0.37, S.E. ± 0.14, *P* \< 0.01) mRNA in the liver. However, backward stepwise regression showed that the expression of *HIF-1α* mRNA in the liver was the only variable that was retained in the model and was strongly correlated with liver mtDNA/nDNA ratio (β: 0.40, S.E.: 0.11, *P* \< 0.001).

Measurement of liver 8-isoprostane as a biomarker of local oxidative stress
---------------------------------------------------------------------------

Isoprostanes are prostaglandin-like compounds produced by free-radical-mediated peroxidation of lipoproteins. Numerous studies have shown that the quantification of isoprostanes is an accurate measure of oxidative stress \[[@b20], [@b21]\]. Evidence from both human and animal studies showed that liver steatosis increases oxidative stress \[[@b22]\]; intracellular levels of reactive oxygen species (ROS) have been found to be associated with changes in mtDNA copy number \[[@b23]\]. To determine whether oxidative stress is related to both hepatic steatosis and mtDNA content, we measured the liver 8-isoprostane levels in both experimental groups, and observed that they were significantly correlated with liver fat content (*R*: 0.42, *P* \< 0.004). Nevertheless, no significant association was observed either with liver mtDNA content or liver *HIF-1α* mRNA expression.

The liver abundance of mRNA of master nuclear genes that regulate normal mitochondrial biogenesis and replication was not associated with the liver mtDNA content
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

To evaluate whether the hepatic expression of other transcription factors was associated with the observed increase in liver mtDNA content, we measured the following: mitochondrial transcription factor (*Tfam*) mRNA (a key regulator of mtDNA copy number required for the replication and maintenance of mtDNA \[[@b24]\]), peroxisome proliferator-activated receptor gamma coactivator-1-α (*PGC-1α*) and -β (*PGC-1β*) mRNA (physiological transcriptional regulators of oxidative metabolism and mitochondrial biogenesis \[[@b24]\]); *PGC-1β* is also considered to preferentially induce the expression of genes involved in the removal of ROS, nuclear respiratory factor-1 (*NRF-1*) mRNA (a gene involved in oxidative stress induced mitochondrial biogenesis \[[@b23]\]), and peroxisome proliferator-activated receptor δ (*PPARδ*) mRNA (a nuclear receptor capable of increasing the skeletal muscle mitochondria even in the absence of an increase in *PGC-1α* mRNA).

On the whole, we observed that the mRNA expression of the above-mentioned genes in the liver was not significantly associated with the liver mtDNA/nDNA ratio. In addition, we found no differences between the groups (HFD *versus* SCD) with regard to the mRNA expression of either of these genes ([Fig. 4](#fig04){ref-type="fig"}).

![Liver mRNA expression of mitochondrial biogenesis genes assessed by quantitative real-time PCR in each experimental group. Each bar represents the mean ± S.E. values of 10 and 15 animals in SCD and HFD, respectively. In each sample, the gene expression was normalized to the expression of cyclophilin A and multiplied by 100. T*fam*: mitochondrial transcription factor A; PPARδ: peroxisome proliferator-activated receptor γ; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator-1α; PGC-1β: peroxisome proliferator-activated receptor gamma coactivator-1β; NRF-1: nuclear respiratory factor 1; PPIA: peptidylprolyl isomerase A (cyclophilin A); NS: not significant.](jcmm0015-1329-f4){#fig04}

Evaluation of hepatic mRNA expression of apoptosis-related genes (Bcl-2, Bax and caspase-3), and fibrosis-related genes (collagen type Iα~1~ and smooth muscle α-actin)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Hepatocyte apoptosis and caspase activation are prominent features of human NALFD \[[@b25], [@b26]\]. In our experimental model, the liver tissue of HFD rats did not show histological signs of liver injury, inflammation or liver fibrosis, and this observation is in agreement with other reports \[[@b27]\]. Even so, to understand the potential role that early events associated with hepatocyte apoptosis might have in the *HIF-1α*-induced increase of the liver mtDNA content, we measured the hepatic mRNA expression of three apoptotic genes, such as: caspase 3 -- a marker of early apoptosis and a reliable indicator of apoptotic rate -- and two members of the Bcl-2 superfamily of proteins, the pro-apoptotic Bax and the anti-apoptotic Bcl-2, which act regulating the permeability of the mitochondrial membrane. Interestingly, the liver mRNA expression of none of the above-mentioned genes was significantly associated with the liver mtDNA/nDNA ratio. In addition, there was no significant difference in the liver Bax/Bcl-2 expression ratio between the groups (HFD *versus* SCD), [Figure 5A](#fig05){ref-type="fig"}. Nevertheless, the levels of hepatic mRNA expression of caspase 3 were significantly higher in the HFD group ([Fig. 5A](#fig05){ref-type="fig"}).

![Liver mRNA expression of apoptosis-related genes (*Bax*, *Bcl2* and *caspase 3*) (A) and a fibrosis-related gene (*Col1a1*) (B), assessed by quantitative real-time PCR in each experimental group. Each bar represents the mean ± S.E. values of 10 and 15 animals in SCD and HFD, respectively. In each sample, the gene expression was normalized to the expression of cyclophilin A and multiplied by 100/1000 as shown. *Bax:* Bcl2-associated X protein; *Bcl2*: *B-cell* CLL/lymphoma 2; *Casp3*: caspase 3; *Col1a1*: collagen type I α~1~. (C) Gomori's reticulin silver impregnation of liver sections at the end of the experiment using a representative rat from each experimental group. Figure shows comparisons of the reticulin pattern of the portal tract and hepatic parenchyma across groups.](jcmm0015-1329-f5){#fig05}

We further evaluated the liver mRNA expression of collagen type I α~1~-- an extracellular matrix component, and smooth muscle α-actin, a marker of activation of resident stellate cells to myofibroblast-like cells, to gauge potential progression along the fibrosis development. There were no significant differences between the groups about liver collagen type I α~1~ mRNA expression ([Fig. 5B](#fig05){ref-type="fig"}); the abundance of smooth muscle α-actin mRNA was completely undetectable in both experimental groups, by our real-time PCR-based method. Moreover, neither the trichrome ([Fig. 1C and D](#fig01){ref-type="fig"}) nor the reticulin stains showed alterations of the collagenous stroma ([Fig. 5C](#fig05){ref-type="fig"}).

Effect of reversion of hepatic steatosis on liver mtDNA content and liver *HIF-1α* mRNA expression
--------------------------------------------------------------------------------------------------

To further understand the role of liver steatosis in *HIF-1α*-mediated increase in the liver mtDNA content, we evaluated the effect of telmisartan -- a type 1 angiotensin II receptor blocker also considered to act as a partial agonist of PPARγ-- on both liver *HIF-1α* mRNA expression and liver mtDNA/nDNA ratio. We chose this pharmacological agent because we previously demonstrated that telmisartan could revert fatty liver in an HFD-induced rat model of NAFLD \[[@b14]\]. In addition, previous evidence also showed that telmisartan could inhibit the generation of ROS and lipid peroxidation products in kidney \[[@b28]\].

The animals were given HFD for 8 weeks and after this period, for 12 weeks, they received vehicle (HFD) or telmisartan (Bago, Buenos Aires, Argentina) at 10 mg/kg intraperitoneally for every 24 hrs, along with the same access to HFD (T + HFD). The liver tissue was then collected to determine the mtDNA content, *HIF-1α,* mitochondria-related mRNA gene expression levels, and liver 8-isoprostane, as described earlier.

Telmisartan was associated with a significant decrease in the liver mtDNA/nDNA ratio ([Fig. 6A](#fig06){ref-type="fig"}) and liver *HIF-1α* mRNA expression ([Fig. 6B](#fig06){ref-type="fig"}). The liver HIF-1α protein level was also decreased in the T + HFD group when compared with the HFD group and SCD group ([Fig. 6D](#fig06){ref-type="fig"}). As shown in [Figure 6C](#fig06){ref-type="fig"}, fatty liver was efficiently reverted by telmisartan. Interestingly, rats treated with telmisartan showed a significant decrease in liver 8-isoprostane levels when compared with the HFD group ([Fig. 6E](#fig06){ref-type="fig"}).

![Effect of telmisartan on the reversion of hepatic steatosis, liver mtDNA content, *HIF-1α* mRNA and protein abundance, and liver 8-isoprostane levels. (A) Liver mtDNA/nDNA ratio assessed by quantitative real-time PCR in each experimental group. \**P* \< 0.029, HFD *versus* SCD; ^\#^*P* \< 0.006, T + HFD *versus* HFD. (B) *HIF-1α* mRNA analysed using quantitative real-time PCR in each experimental group. \**P* \< 0.03, HFD *versus* SCD; ^\#^*P* \< 0.0001, T + HFD *versus* HFD. (C) Liver histology of a representative animal from each experimental group. Haematoxylin and eosin, Masson's trichrome and osmium tetroxide staining of liver sections at the end of the experiment using a representative rat from each experimental group as described in the 'Materials and methods' section. (D) Representative Western blot analysis of liver *HIF-1α* protein levels in each experimental group. Hypoxia-positive control (H) obtained from a rat ischemic skeletal muscle. β-actin was used as loading control. (E) Liver 8-isoprostane levels as a biomarker of local oxidative stress, assessed by ELISA in each experimental group. The results expressed as ng/mg liver protein. \**P* \< 0.004, HFD *versus* SCD; ^\#^*P* \< 0.0001, T + HFD *versus* HFD, adjusted by liver triglyceride content using ANCOVA. SCD: standard chow diet, HFD: high-fat diet; T + HFD: telmisartan plus high-fat diet.](jcmm0015-1329-f6){#fig06}

Discussion
==========

Progress in the understanding of the pathophysiology of NAFLD has been partly made through the evaluation of the molecular events that occur in the liver of experimental models. Using an HFD-induced rat model of NAFLD, we reproduced the features of human liver steatosis to evaluate the liver mtDNA content. We observed that feeding of rats with HFD resulted in an increase in the liver mtDNA/nDNA ratio, and this increase, was modestly but significantly correlated with the liver triglyceride content. We also found that livers of rats with increased mtDNA copy number also appear to have higher mitochondrial density, as assessed by electron microscopy. We further suggested that this increase in mtDNA copy number might be regulated by liver *HIF-1α*. Thus, this study, for the first time, demonstrated that the observed increase in the liver mtDNA/nDNA ratio was associated with the expression of *HIF-1α* mRNA in the liver. In addition, we provided further evidence to the hypoxic-mediated increase in liver mitochondrial biogenesis by demonstrating that liver *COX4I1* mRNA expression was positively correlated with liver mtDNA content. We found that an increase in the mitochondrial mass was also supported by the increased expression of *COX4I1* mRNA.

Furthermore, we also evaluated the mRNA expression in the liver of several key transcriptional factors, which are known to regulate normal mitochondrial biogenesis, including, *PGC-1α, PGC-1*β, *NRF-1*, *PPARδ* and *Tfam*, and observed that the increase in liver mitochondrial biogenesis was not related to the expression of the genes that commonly regulate mtDNA content. Additionally, we also observed that oxidative stress, although increased by HFD, was not directly involved in the *HIF-1α*-mediated increase in mtDNA copy number. Similarly, while liver caspase 3 mRNA levels were higher in the HFD group suggesting the presence of early apoptotic events, they were not associated with the changes observed in the liver mtDNA content.

Finally, to explore whether the observed events were related to the presence of liver steatosis, we evaluated the liver mtDNA content and *HIF-1α* mRNA expression in rats treated with telmisartan (a pharmacological agent that was found to efficiently revert back fatty liver \[[@b14]\]). Treatment of rats with telmisartan resulted in a significant decrease in liver mtDNA/nDNA ratio as well as liver *HIF-1α* mRNA and protein level. Otherwise, telmisartan may be involved directly in the modulation of *HIF-1α*. This observation is supported by previous evidence that showed that chronic hypoxia is associated with activation of the renin--angiotensin system \[[@b29], [@b30]\]. Thus, it is reasonable to hypothesize that the blockade of the renin--angiotensin system may directly prevent the effects of the induction of *HIF-1α*.

Although these results are novel, they are in agreement with earlier studies that showed that HFD could induce increase in mitochondrial enzymes and mitochondrial biogenesis in muscle \[[@b31], [@b32]\].

Furthermore, the central finding of our study, *i.e. HIF-1α*-associated increase in liver mtDNA content, is also supported by previous experimental observations on other tissues. For instance, neuronal mitochondrial biogenesis was highly increased after hypoxia or hypoxic--ischemic injury \[[@b13], [@b33]\].

Interestingly, although hypoxia has been well defined as an important mediator of inflammation and insulin resistance \[[@b34]\], its role in fatty liver disease, particularly in modulating liver mtDNA content, was never described previously.

The most important finding of our study is the potential role that hypoxia seems to have in the molecular events related to the increased accumulation of fat in the liver, and its impact on mitochondrial function. This concept was initially described in ethanol-induced steatohepatitis \[[@b35]\]. Moreover, Mantena *et al*. showed that chronic exposure of rats to HFD could affect liver mitochondrial function and cause hepatocyte hypoxia \[[@b10]\]. These findings were also replicated in human studies. Fisher *et al*. recently evaluated the microsomes isolated from human liver samples, and observed that NAFLD progression was correlated with elevated *HIF-1α* expression \[[@b36]\]. Finally, the increased hepatocyte lipid content was shown as a key determinant of hepatocyte sensitivity to hypoxia, an observation that has a direct clinical impact on, for instance, decreased viability of donor steatotic liver after liver transplantation \[[@b37]\].

In summary, accumulating evidence suggests a major role of mitochondrial dysfunction in the physiopathology of NAFLD. Nevertheless, only a few studies have explained how lipid accumulation in the hepatocytes affects liver mtDNA content. We consider that the main objective of our study was to provide evidence on the notion that hypoxia may play a role in the mitochondrial changes associated with NAFLD.

In addition, the biological and prognostic implications of our findings are as follows. Based on our experimental results, it seems reasonable to speculate that the observed increase in mtDNA content is an adaptive mechanism either to enhance the liver mitochondrial function to manage the increased mitochondrial β-oxidation as well as protect the hepatocytes against lipid peroxidation, or to compensate the hypoxic condition resulting from microcirculatory disturbances associated with fatty liver \[[@b38]\]. However, this aspect deserves further investigation.

It is worth mentioning that we did not observe either inflammatory changes or fibrosis in the liver, and that the histological lesions were limited to the accumulation of lipids in the hepatocytes -- a morphological change also known as simple steatosis. This seems to be a hallmark as well as a limitation of this particular rodent model. Hence, we can hypothesize that changes in mtDNA precede liver lipotoxicity damage with the subsequent progression to more severe disease, which is in agreement with previous works that have demonstrated that either intermittent or sustained exposure to hypoxia results in steatohepatitis \[[@b39], [@b40]\]. This observation has clinical relevance because the observed changes in mtDNA can be reverted using any intervention that can improve liver steatosis. Furthermore, our observations on the effects of telmisartan on improving fatty liver infiltration as well as decreasing liver mtDNA content and expression of *HIF-1α* in the liver are in agreement with this finding.

Finally, the presence of increased mtDNA content in the steatotic liver, either as an outcome of chronic effects of hepatocyte hypoxia or an adaptive mechanism to enhance mitochondrial function, needs to be assessed further in the context of advanced lesions of NAFLD, including necroinflammatory response and fibrosis, to evaluate whether the increase in liver mtDNA confers a physiological advantage during the initial stages of NAFLD.

This study was partially supported by the grants PICT 2006--124 (Agencia Nacional de Promoción CientÌfica y Tecnológica) and UBACYT M055 (Universidad de Buenos Aires). A.B., M.S.R., T.F.G., C.J.P. and S.S. are members of Consejo Nacional de Investigaciones CientÌficas.

Conflict of interest
====================

The authors confirm that there are no conflicts of interest.

[^1]: These authors should be considered as first authors.
